Bob Duggan loaned his company Summit Therapeutics ~$500 million to allow the firm to purchase the rights to an investigational drug called Ivonescimab in the US, the UK, and other countries. The […]
Bob Duggan’s pharmaceutical company Summit Therapeutics paid $500 million in upfront licensing fees to the Chinese pharmaceutical company Akeso, Inc. (HKEX Code: 9926. HK). This was cash/stock deal that was finalized in […]
The Dianetics Center of Islamabad, Pakistan is managed by Los Angeles Scientologists Marijke and Zahid Qureshi. Why Dianetics Islamabad cannot be trusted to have local management raises serious concerns: Why doesn’t Scientology […]
As we previously reported, Scientologist Matt Feshbach and his investors sold their Okyanos Heart Institute in the Bahamas sometime in 2017. Okyanos having been sold, Matt Feshbach next ran into a brick […]
By Jeffrey Augustine Elena Cardone posted this on Facebook. She convinced Grant to open a non-accredited fund for friends and family. Elena mentions that this all per FCC rules. Memo to Elena: […]
The image above is from 2007 and was published in a Scientology magazine I received in the US mail many years ago. I posted several photos of Sea Org members contained in […]
The Scientology Money Project did an article recently on the US Bankruptcy Court’s denial of Matt and Kathy Feshbach’s attempt to discharge $3.8 million in back taxes via bankruptcy. This led me […]
An excellent article in Forbes by Jay D. Adkisson concerns Scientologists Matt and Kathy Feshbach. Adkisson’s article was the feature subject of a recent column Tony Ortega’s Underground Bunker. The community commentary […]
The Church of Scientology is infamous for its rabid attacks on Psychiatry and what it calls “Big Pharma.” In the tweet above we see Scientologist and OSA operative John Alex Wood going […]
IRS tax forms show that the Scientology billionaire power couple Bob and Trish Duggan placed 1,000,000 shares of AbbVie Inc., a pharmaceutical manufacturer, into their private foundation in December 2015. At that […]
